Melatonin, vitamins and minerals supplements for the treatment of Covid-19 and Covid-like illness: A prospective, randomized, double-blind multicenter study

被引:5
作者
Mahjoub, Lobna [1 ]
Youssef, Rym [1 ]
Yaakoubi, Hajer [1 ]
Ben Salah, Houda [1 ]
Jaballah, Rahma [1 ]
Mejri, Moez [1 ]
Sekma, Adel [2 ]
Trabelsi, Imen [2 ]
Nouira, Semir [2 ]
Khrouf, Mariem [3 ]
Ben Soltane, Houda [3 ]
Mezgar, Zied [3 ]
Boukadida, Lotfi [1 ]
Zorgati, Asma [1 ]
Boukef, Riadh [1 ]
机构
[1] Sahloul Univ Hosp, Emergency Dept, Sousse 4011, Tunisia
[2] Monastir Univ, Res Lab LR12SP18, Monastir 5019, Tunisia
[3] Farhat Hached Univ Hosp, Emergency Dept, Sousse 4031, Tunisia
关键词
Melatonin; Zinc; Vitamin C; Vitamin D; Covid-19; Emergency department; INFECTION; ZINC;
D O I
10.1016/j.explore.2023.06.009
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Background: Melatonin, zinc, and multivitamins are among most recommended supplements in the fight against coronavirus disease 2019 (COVID-19). We aimed to examine the efficacy and safety of this association in the treatment of COVID-19 and COVID-like illnesses. Methods: We conducted a multicenter prospective, randomized, double-blind, controlled trial. Patients with no medical history consulting the emergency department for covid and covid-like illness and who were not hospitalized were included. Patients were assigned in a 1:1 ratio to the treatment or the placebo group. The primary outcome was studying the effectiveness of zinc multivitamin supplement and melatonin in the treatment of COVID and -like illnesses symptoms' according to the time from randomization to clinical improvement. The prespecified secondary outcomes were date of disappearance of symptoms present on admission, appearance of an adverse effect due to the administration of the treatment, number of patients developing complications, requiring hospitalization, requiring respiratory support. Results: One hundred sixty four patients were eligible for the study and were randomized to either the treatment group or the placebo group. Overall, 128 of the 164 patients had a PCR for SARS-CoV-2, yielding a positive PCR result in 49.1% of them. Regarding the disappearance of all initial presenting symptoms: on the 5(th) day of the follow-up, there was a significant difference between the two groups with a p value 0.04;On the 10th day, there was a significant difference too with p value of 0.038. There were no significant differences between the two groups in recovery during the 15th day of follow-up p>0.5. Finally, 100% of patients fully recovered in the treatment group vs 98.8% in the placebo group. No severe adverse events were reported throughout the trial. Conclusions: Our results showed that daily doses of Melatonin, zinc and vitamins did significantly reduce the duration of symptoms accelerating its disappearance among patients consulting with COVID-19 or COVID-19 like illness.
引用
收藏
页码:95 / 100
页数:6
相关论文
共 50 条
  • [31] Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trial
    Anan Manomaipiboon
    Kittisak Pholtawornkulchai
    Sujaree Poopipatpab
    Swangjit Suraamornkul
    Jakravoot Maneerit
    Wiroj Ruksakul
    Uraporn Phumisantiphong
    Thananda Trakarnvanich
    Trials, 23
  • [32] Efficacy and safety of add-on Viola odorata L. in the treatment of COVID-19: A randomized double-blind controlled trial
    Mehraban, Mohammad Sadegh Adel
    Shirzad, Meysam
    Kashani, Leila Mohammad Taghizadeh
    Ahmadian-Attari, Mohammad Mahdi
    Safari, Ali Akbar
    Ansari, Narges
    Hatami, Hossein
    Kamalinejad, Mohammad
    JOURNAL OF ETHNOPHARMACOLOGY, 2023, 304
  • [33] Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trial
    Manomaipiboon, Anan
    Pholtawornkulchai, Kittisak
    Poopipatpab, Sujaree
    Suraamornkul, Swangjit
    Maneerit, Jakravoot
    Ruksakul, Wiroj
    Phumisantiphong, Uraporn
    Trakarnvanich, Thananda
    TRIALS, 2022, 23 (01)
  • [34] Efficacy of naproxen in the management of patients hospitalized with COVID-19 infection: A randomized, double-blind, placebo-controlled, clinical trial
    Asadi, Masoomeh
    Sayar, Sara
    Radmanesh, Esmat
    Naghshi, Sina
    Mousaviasl, Sajedeh
    Jelvay, Saeed
    Ebrahimzadeh, Mona
    Mohammadi, Asma
    Abbasi, Samaneh
    Mobarak, Sara
    Bitaraf, Saeid
    Zardehmehri, Fatemeh
    Cheldavi, Ali
    DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2021, 15 (06)
  • [35] Positive Effects of Vitamin D Supplementation in Patients Hospitalized for COVID-19: A Randomized, Double-Blind, Placebo-Controlled Trial
    De Niet, Sophie
    Tremege, Mickael
    Coffiner, Monte
    Rousseau, Anne-Francoise
    Calmes, Doriane
    Frix, Anne-Noelle
    Gester, Fanny
    Delvaux, Muriel
    Dive, Anne-Francoise
    Guglielmi, Elora
    Henket, Monique
    Staderoli, Alicia
    Maesen, Didier
    Louis, Renaud
    Guiot, Julien
    Cavalier, Etienne
    NUTRIENTS, 2022, 14 (15)
  • [36] Effect of nasal corticosteroid in the treatment of anosmia due to COVID-19: A randomised double-blind placebo-controlled study
    Rashid, Rasheed Ali
    Zgair, Atheer
    Al-Ani, Raid M.
    AMERICAN JOURNAL OF OTOLARYNGOLOGY, 2021, 42 (05)
  • [37] Safety and efficacy of favipiravir in COVID-19 patients with pneumonia. A randomized, double-blind, placebo-controlled study (FAVID)
    Juan P. Horcajada
    Rebeca Aldonza
    Mónica Real
    Silvia Castañeda-Espinosa
    Elena Sendra
    Joan Gomez-Junyent
    Inmaculada López-Montesinos
    Silvia Gómez-Zorrilla
    Silvia Briansó
    Montserrat Duran-Taberna
    Andrés Fernández
    Cristina Tarragó
    Teresa Auguet-Quintillá
    Pneumonia, 16
  • [38] Steroid in the Treatment of Outpatient COVID-19: A Multicenter Randomized Controlled Trial
    Amra, Babak
    Vaezi, Atefeh
    Soltaninejad, Forogh
    Salahi, Mehrdad
    Salmasi, Mehrzad
    Javanmard, Shaghayegh Haghjooy
    ADVANCED BIOMEDICAL RESEARCH, 2023, 12 (01):
  • [39] Probiotic Therapy of Gastrointestinal Symptoms During COVID-19 Infection: A Randomized, Double-Blind, Placebo-Controlled, Remote Study
    Horvath, Angela
    Haller, Rosa
    Feldbacher, Nicole
    Habisch, Hansjoerg
    Zukauskaite, Kristina
    Madl, Tobias
    Stadlbauer, Vanessa
    NUTRIENTS, 2024, 16 (22)
  • [40] Randomized double-blind clinical study in patients with COVID-19 to evaluate the safety and efficacy of a phytomedicine (P2Et)
    Uruena, Claudia
    Ballesteros-Ramirez, Ricardo
    Gomez-Cadena, Alejandra
    Barreto, Alfonso
    Prieto, Karol
    Quijano, Sandra
    Aschner, Pablo
    Martinez, Carlos
    Zapata-Cardona, Maria, I
    El-Ahanidi, Hajar
    Jandus, Camilla
    Florez-Alvarez, Lizdany
    Rugeles, Maria Teresa
    Zapata-Builes, Wildeman
    Garcia, Angel Alberto
    Fiorentino, Susana
    FRONTIERS IN MEDICINE, 2022, 9